The company operates a recording studio in Kolkata and manages music rights while also engaging in the trading and investment of equity shares and securities.
The company lacks a durable competitive advantage, as evidenced by its reliance on non-operational investment income and a music segment with stagnant revenues and obsolete physical inventory. Financial metrics show negative net margins and negligible returns on capital, contradicting any claim of a structural moat.
Capital is primarily deployed into interest-free loans and advances to third parties and unquoted equity investments rather than being reinvested into the core entertainment business. This strategy has resulted in consistent value destruction, with an average net margin of -24.9% and no dividend distributions.
The company's slow-motion liquidation concluded as the interest-free loans to third parties—representing the bulk of its assets—were never recovered, and the unquoted equity investments proved worthless. The core music business, already burdened by obsolete physical inventory and stagnant revenue, finally collapsed under its own weight. As the promoter group continued to liquidate shares to satisfy regulatory penalties, the remaining capital was drained by non-operational expenses, leaving shareholders with a hollow shell that lacks both cash and a viable business model.
RichFakir rates JMD Ventures Ltd's business quality as poor — 9/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, JMD Ventures Ltd is trading about 94% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on JMD Ventures Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of JMD Ventures Ltd's fair value is about ₹3 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →